Novavax's vaccines utilize what are called virus-like particles--genetically engineered molecules designed to train the immune system to recognize a particular virus.
That means that lots of people in the study are likely to be exposed to it, and it will be possible to see if the 2, 000 participants who receive Novavax's shots get confirmed infections less than the 1, 000 who don't.